The content on this site is intended for healthcare professionals only
Dr Oxnard speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the prospects of a simple blood test for cell-free DNA (cfDNA) to detect lung cancers.
He discusses how 3 assays for targeted sequencing, whole-genome sequencing and whole-genome bisulfites sequencing can detect the circulating biomarkers of lung cancer, and considers how these could eventually be incorporated into screening and care.
For more on these results, watch his interview with ecancer, and read our news coverage here.
Slides from this presentation are available here.
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Lung Cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 4th - 10th, 2023
Choosing Wisely in radiology Tanzania
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
